Infliximab is a monoclonal chimeric antibody, with high affinity and specificity for tumour necrosis factor alpha (TNFalpha) that plays a central role in the pathogenesis of immune mediated inflammatory disorders including Crohn's disease and ulcerative colitis. Globally over 600000 patients have been treated with infliximab to date. This global experience led to a better definition of the overall safety and efficacy profile of this medication. The goal of the present recommendations is to provide practical information to physicians involved in the care of patients with inflammatory bowel disease
The introduction of tumor necrosis factor (TNF) inhibitors has significantly changed the treatment l...
Infliximab is a chimeric monoclonal antibody against anti-tumour necrosis factor alpha that has chan...
Abstract: Crohn\u2019s disease (CD) is a chronic inflammatory disease of the gastrointestinal tract ...
Infliximab is a monoclonal chimeric antibody, with high affinity and specificity for tumour necrosis...
Infliximab is a monoclonal chimeric antibody, with high affinity and specificity for tumour necrosis...
Infliximab is an accepted induction and maintenance treatment for patients with Crohn's disease. The...
Infliximab is an accepted induction and maintenance treatment for patients with Crohn's disease. The...
peer reviewedCrohn's disease (CD) is a chronic inflammatory disease of the bowel characterized by se...
Infliximab is a chimeric, monoclonal anti-tumour necrosis factor-alpha antibody. It has been previou...
Infliximab is a chimeric, monoclonal anti-tumour necrosis factor-alpha antibody. It has been previou...
Infliximab is a chimeric monoclonal antibody to human tumor necrosis factor alpha. While its use was...
BACKGROUND: Guidelines regarding the use of infliximab in Crohn’s disease were previously published ...
Les auteurs font une revue des nouveaux traitements de la maladie de Crohn basés sur des agents biol...
5-aminosalicylates preparations are not superior to placebo for the maintenance of medically-induced...
Antitumor necrosis factor a agents have significantly improved the management of Crohn's disease (CD...
The introduction of tumor necrosis factor (TNF) inhibitors has significantly changed the treatment l...
Infliximab is a chimeric monoclonal antibody against anti-tumour necrosis factor alpha that has chan...
Abstract: Crohn\u2019s disease (CD) is a chronic inflammatory disease of the gastrointestinal tract ...
Infliximab is a monoclonal chimeric antibody, with high affinity and specificity for tumour necrosis...
Infliximab is a monoclonal chimeric antibody, with high affinity and specificity for tumour necrosis...
Infliximab is an accepted induction and maintenance treatment for patients with Crohn's disease. The...
Infliximab is an accepted induction and maintenance treatment for patients with Crohn's disease. The...
peer reviewedCrohn's disease (CD) is a chronic inflammatory disease of the bowel characterized by se...
Infliximab is a chimeric, monoclonal anti-tumour necrosis factor-alpha antibody. It has been previou...
Infliximab is a chimeric, monoclonal anti-tumour necrosis factor-alpha antibody. It has been previou...
Infliximab is a chimeric monoclonal antibody to human tumor necrosis factor alpha. While its use was...
BACKGROUND: Guidelines regarding the use of infliximab in Crohn’s disease were previously published ...
Les auteurs font une revue des nouveaux traitements de la maladie de Crohn basés sur des agents biol...
5-aminosalicylates preparations are not superior to placebo for the maintenance of medically-induced...
Antitumor necrosis factor a agents have significantly improved the management of Crohn's disease (CD...
The introduction of tumor necrosis factor (TNF) inhibitors has significantly changed the treatment l...
Infliximab is a chimeric monoclonal antibody against anti-tumour necrosis factor alpha that has chan...
Abstract: Crohn\u2019s disease (CD) is a chronic inflammatory disease of the gastrointestinal tract ...